EverSource Wealth Advisors’s MaxCyte MXCT Stock Holding History

EverSource Wealth Advisors’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$980	Buy	1,395 +619	+80%	+$578	﹤0.01%	3861
2025 Q4	$1.2K	Sell	776 -243	-24%	-$388	﹤0.01%	3662
2025 Q3	$1.61K	Buy	1,019 +205	+25%	+$356	﹤0.01%	3582
2025 Q2	$1.77K	Buy	814 +339	+71%	+$821	﹤0.01%	3544
2025 Q1	$1.3K	Buy	475 +361	+317%	+$1.42K	﹤0.01%	3127
2024 Q4	$474	Buy	+114	New	+$431	﹤0.01%	3218
2022 Q1	–	Sell	-243	Closed	-$2K	–	1797
2021 Q4	$2K	Buy	+243	New	+$2.61K	﹤0.01%	1582

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $641M AUM 61.79% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFM

Brooklands Fund Management London, United Kingdom $88.9M AUM

EverSource Wealth Advisors's MXCT Position: Q1 2026 in Review

EverSource Wealth Advisors increased its MaxCyte (MXCT) stake by 80% in Q1 2026, buying an estimated $578 and bringing the position to 1,395 shares worth $980. The position accounts for ﹤0.01% of the portfolio, ranked #3861.

EverSource Wealth Advisors first reported a position in MXCT in Q4 2021 and has held it in 7 quarters since. The position peaked at $2K in Q4 2021. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

EverSource Wealth Advisors held 1,395 shares of MaxCyte worth $980 as of Q1 2026.
EverSource Wealth Advisors bought 619 MaxCyte shares in Q1 2026, an estimated $578.
MaxCyte made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #3861 holding.
EverSource Wealth Advisors first reported a position in MaxCyte in Q4 2021 and has held it in 7 quarters since.
EverSource Wealth Advisors's MaxCyte position peaked at $2K in Q4 2021.
130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.